This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pfizer Needs Big Earnings Beat

NEW YORK ( TheStreet) -- Falling earnings don't make for a strong stock; however, Pfizer's (PFE - Get Report) shares have continued to move higher.

Who They Are: Pfizer is a research-based, global pharmaceutical company that trades an average of 56.4 million shares per day with a marketcap of $175 billion.

Pfizer is forecast to record lackluster second-quarter earnings before the market opens on July 31. The consensus estimate is currently 55 cents a share, a fall of 5 cents (8.3%) from 60 cents during the equivalent quarter last year.

Fifteen out of 17 analysts covering the stock (over 70%) rate Pfizer a buy or strong buy. The company has two holds, and not one sell rating. The stock has appreciated 19.1% in the last year, and the average analyst target price for PFE is $25.58.

May 1 was the last earnings release with a closing price of $22.78, compared to a current price of $23.33. (Read a recent bullish article including Pfizer Are Elan, Pfizer, Lilly and J&J Buys After a Failed Drug Test? )

Management is executing with an increase of year-over-year revenue. Revenue reported was $67.43 billion last fiscal year compared to $67.06 billion in the previous year. The bottom line has rising earnings year-over-year of $10.01 billion last fiscal year compared to $8.26 billion in the previous year.

PFE beat earnings in all four of the last four quarters, with an average beat of 3 cents (5.56%) per share.

PFE PE Ratio Chart PFE PE Ratio data by YCharts

Industry and peer comparisons of companies that report before Pfizer:

Johnson & Johnson (JNJ - Get Report) recently beat earnings by a penny with $1.30 EPS. Wall Street wasn't pleased and shares have fallen about $2 a share to trade near $67.50.

Analysts as a whole like this company. Currently, J&J has 15 buy recommendations out of 23 analysts covering the company, eight holds and zero sell ratings. Over half the analysts covering J&J rate it as a buy or a strong buy.

J&J has appreciated 2.2% in the last year, and the average analyst target price for J&J is $74.60. J&J has a sizeable short interest of 9.5%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BMY $64.50 -1.92%
GILD $98.13 -2.54%
JNJ $100.60 -0.94%
MRK $57.48 -1.47%
PFE $34.79 -0.60%


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs